WCLC 2025 - Posters & ePosters-P3.18.03 Implementation Study of Lung Cancer Screening Combined With a Smoking Cessation RCT in the Flemish Region: The ZORALCS- and TAMIRO-Stop-Study

P3.18.03 Implementation Study of Lung Cancer Screening Combined With a Smoking Cessation RCT in the Flemish Region: The ZORALCS- and TAMIRO-Stop-Study

Back to course

Pdf Summary

The ZORALCS- and TAMIRO-STOP studies in the Flemish region aim to evaluate lung cancer screening combined with smoking cessation efforts in high-risk adults with heavy (former) smoking habits. Lung cancer is the leading cause of cancer deaths globally and in Belgium. Annual Low-Dose Computed Tomography (LDCT) screening has been scientifically shown to reduce mortality in high-risk populations. Following a 2022 European Council recommendation to explore LDCT screening implementation, ZORALCS and TAMIRO-STOP focus on tailored, equitable, population-based approaches.<br /><br />The ZORALCS study is a four-year, prospective, monocentric, non-randomized feasibility and implementation study targeting adults aged 55-74 in the ZORA primary care zone near Antwerp, Belgium. Recruitment involves sending invitation letters to 25,885 adults, with eligibility assessed by validated risk models (PLCOm2012 and HUNT). Approximately 700 participants are expected. The primary aim is to determine the participation rate for at least one LDCT scan. Secondary aims include assessing compliance, incidental findings, radiation exposure, and informed decision-making. Participants undergo LDCT at Antwerp University Hospital, with reports generated per ESTI guidelines and AI-assisted volumetric analysis. Patient-Reported Experience Measures are collected pre-scan. Follow-up depends on nodule management, including short-term (1, 3, 6 months) and annual screening rounds.<br /><br />TAMIRO-STOP is a two-year randomized controlled trial nested within ZORALCS, enrolling participants who currently smoke or quit less than one year prior. Via an online platform, participants provide consent and are randomly assigned (1:1) to either minimal care (brief motivational interview and referral resources) or structured intervention (brief motivational interview plus 8 free tobaccologist sessions and 12-week nicotine replacement). Primary outcome is smoking cessation measured by point prevalence abstinence at one year, with CO-measurements at baseline and after one year.<br /><br />The studies began in January 2024, with recruitment starting in March 2025 and data analysis planned for 2027. This integrated approach aims to assess the feasibility, effectiveness, and acceptability of combining LDCT lung cancer screening with proactive smoking cessation interventions in a high-risk population to reduce lung cancer mortality.

Asset Subtitle

Charlotte Theuns

Meta Tag

Speaker Charlotte Theuns

Topic Clinical Trials in Progress

Keywords

Lung cancer screening

Low-Dose Computed Tomography (LDCT)

Smoking cessation

ZORALCS study

TAMIRO-STOP trial

High-risk adults

Belgium

PLCOm2012 risk model

Randomized controlled trial

Lung cancer mortality reduction